ARAF Inhibitors
1 drugsAbout ARAF
ARAF is a serine/threonine-protein kinase in the RAF family, part of the RAS/MAPK signaling pathway that regulates cell growth and differentiation. Dysregulation of this pathway is common in cancers, leading to uncontrolled cell growth.
ARAF's role in the RAS/MAPK pathway makes it a compelling oncology target, though there is currently no genetic evidence directly linking ARAF to specific diseases.
One FDA-approved drug, ZELBORAF (Roche), targets the RAF family, demonstrating the clinical viability of modulating this pathway. ZELBORAF, a small molecule, was first approved in 2011 and is the only approved drug.
Top ARAF Drugs
Roche is the only company with an approved drug targeting this pathway.
The market is highly concentrated, posing a barrier to entry.
ARAF Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets ARAF, using small molecule modality.
Explore novel modalities to differentiate from existing therapies.
ARAF Clinical Trials 121 trials
Phase 1-4 trials started in 2008 or later that test an FDA-approved drug acting on ARAF. Source: ClinicalTrials.gov. How we count
Completion by Phase
| Phase | Total | Completed | Stopped | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 46 | 28 | 15 | 2 | 65% |
| Phase 2 | 61 | 25 | 14 | 22 | 64% |
| Phase 3 | 10 | 7 | 1 | 2 | 88% |
| Phase 4 | 4 | 2 | 1 | 1 | 67% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Phase 3 Readout Calendar Pro
1 Phase 3 trial testing approved ARAF drugs across all sponsors.
Coverage: trials whose intervention is an approved drug targeting ARAF. Pre-approval candidates with development codes (e.g. AZD0901, MK-7240) are not yet linked. Anchored on CT.gov primary completion date.
ARAF Drug Approval Timeline (2011 - 2011)
The first and only drug, ZELBORAF, was approved in 2011.
The lack of recent approvals suggests a saturated market or challenges in developing new therapies.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Sponsors: 66 (13 companies)
- • Completion rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Count Trials
- Trials: phase 1-4 interventional trials on ClinicalTrials.gov that started in 2008 or later and test an FDA-approved drug acting on ARAF. A trial counts if an approved drug acting on ARAF is in any arm, including as a comparator, and a trial that tests two such drugs counts once. Trials that test only unapproved drugs are not counted. A trial listed as phase 1/2 counts as phase 1, and phase 2/3 as phase 2.
- Active: recruiting, not yet recruiting, enrolling by invitation, or active and no longer recruiting.
- Completion rate: of the trials that have ended, the share marked Completed rather than Terminated or Withdrawn. Completed means the trial ended as planned; it does not mean the drug worked. Suspended trials are not counted as ended.
- Stopped: terminated or withdrawn. Trials stop for many reasons, including slow enrolment and business decisions, not only safety or efficacy.
- Sponsors: the lead sponsor of each trial. Companies are the sponsors ClinicalTrials.gov classes as industry; the rest are universities, hospitals, cooperative groups, government bodies and individuals.